静脉注射混合胶束植物烯二酮(维生素K1)与传统疗法治疗犬猫抗凝血杀鼠剂中毒的比较:回顾性研究。

IF 1.7 4区 农林科学 Q2 VETERINARY SCIENCES
G Agostini, E T Mooney, Elw Wilkie, J D White
{"title":"静脉注射混合胶束植物烯二酮(维生素K1)与传统疗法治疗犬猫抗凝血杀鼠剂中毒的比较:回顾性研究。","authors":"G Agostini, E T Mooney, Elw Wilkie, J D White","doi":"10.1111/avj.70004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ingestion of anticoagulant rodenticide is among the most common toxicoses seen in dogs and cats. Current treatment protocols in veterinary patients recommend the use of plasma-containing blood products to replenish clotting factors. Intravenous mixed-micelle phytomenadione (MMP) represents a safe and cost-effective alternative to traditional therapy.</p><p><strong>Objective: </strong>Description of the use of MMP as a treatment for clinical anticoagulant rodenticide toxicosis, focusing on the incidence of adverse reactions and restoration of coagulation times. Duration of hospitalisation, cost of treatment and need for red blood cell-containing products were compared between two cohorts of patients receiving MMP and traditional therapy with blood products.</p><p><strong>Methods: </strong>Retrospective search of electronic medical records from two Australian emergency and referral hospitals for patients treated for clinical anticoagulant rodenticide toxicosis between July 2021 and July 2024.</p><p><strong>Results: </strong>74 animals (71 dogs, 3 cats) were treated for anticoagulant rodenticide toxicosis within the study period. 44 dogs comprised the \"control\" group, and 27 dogs and 3 cats comprised the \"MMP\" group. One dog was excluded from each group. There was no difference in survival to discharge between groups (P = 0.28). No adverse reactions to MMP were recorded. Dogs within the \"control\" group were significantly more likely to receive fresh frozen plasma (FFP), there was no difference in requirement for red blood cell-containing products between groups (P = 1). Animals in the MMP group had significantly shorter hospitalisation time when compared with the control group (P = 0.01).</p><p><strong>Conclusion: </strong>Based on red cell transfusion requirements and survival data in this case series, it can be suggested that MMP is a comparable and cost-effective treatment alternative for clinical anticoagulant rodenticide toxicosis.</p>","PeriodicalId":8661,"journal":{"name":"Australian Veterinary Journal","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of intravenous mixed micelle phytomenadione (vitamin K1) and traditional therapies for the treatment of anticoagulant rodenticide toxicosis in dogs and cats: a retrospective study.\",\"authors\":\"G Agostini, E T Mooney, Elw Wilkie, J D White\",\"doi\":\"10.1111/avj.70004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ingestion of anticoagulant rodenticide is among the most common toxicoses seen in dogs and cats. Current treatment protocols in veterinary patients recommend the use of plasma-containing blood products to replenish clotting factors. Intravenous mixed-micelle phytomenadione (MMP) represents a safe and cost-effective alternative to traditional therapy.</p><p><strong>Objective: </strong>Description of the use of MMP as a treatment for clinical anticoagulant rodenticide toxicosis, focusing on the incidence of adverse reactions and restoration of coagulation times. Duration of hospitalisation, cost of treatment and need for red blood cell-containing products were compared between two cohorts of patients receiving MMP and traditional therapy with blood products.</p><p><strong>Methods: </strong>Retrospective search of electronic medical records from two Australian emergency and referral hospitals for patients treated for clinical anticoagulant rodenticide toxicosis between July 2021 and July 2024.</p><p><strong>Results: </strong>74 animals (71 dogs, 3 cats) were treated for anticoagulant rodenticide toxicosis within the study period. 44 dogs comprised the \\\"control\\\" group, and 27 dogs and 3 cats comprised the \\\"MMP\\\" group. One dog was excluded from each group. There was no difference in survival to discharge between groups (P = 0.28). No adverse reactions to MMP were recorded. Dogs within the \\\"control\\\" group were significantly more likely to receive fresh frozen plasma (FFP), there was no difference in requirement for red blood cell-containing products between groups (P = 1). Animals in the MMP group had significantly shorter hospitalisation time when compared with the control group (P = 0.01).</p><p><strong>Conclusion: </strong>Based on red cell transfusion requirements and survival data in this case series, it can be suggested that MMP is a comparable and cost-effective treatment alternative for clinical anticoagulant rodenticide toxicosis.</p>\",\"PeriodicalId\":8661,\"journal\":{\"name\":\"Australian Veterinary Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australian Veterinary Journal\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1111/avj.70004\",\"RegionNum\":4,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Veterinary Journal","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/avj.70004","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:摄入抗凝血灭鼠剂是狗和猫最常见的中毒之一。目前兽医患者的治疗方案建议使用含血浆的血液制品来补充凝血因子。静脉注射混合胶束植物甲二酮(MMP)是一种安全、经济的传统治疗方法。目的:描述MMP作为临床抗凝剂灭鼠剂中毒的治疗方法,重点介绍其不良反应发生率和凝血恢复时间。比较了两组接受MMP和传统血液制品治疗的患者的住院时间、治疗费用和对含红细胞产品的需求。方法:回顾性检索澳大利亚两家急诊和转诊医院在2021年7月至2024年7月期间治疗临床抗凝血剂杀鼠剂中毒的患者的电子病历。结果:74只动物(71只狗,3只猫)在研究期间被治疗为抗凝血灭鼠剂中毒。44只狗组成“对照组”,27只狗和3只猫组成“MMP”组。每组排除一只狗。两组患者的生存至出院时间无差异(P = 0.28)。MMP无不良反应记录。对照组的狗接受新鲜冷冻血浆(FFP)的可能性显著增加,两组之间对含红细胞产品的需求没有差异(P = 1)。与对照组相比,MMP组动物的住院时间明显缩短(P = 0.01)。结论:根据该病例系列的红细胞输血需求和生存数据,可以提示MMP是临床抗凝血杀鼠剂中毒的一种可比较且具有成本效益的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison of intravenous mixed micelle phytomenadione (vitamin K1) and traditional therapies for the treatment of anticoagulant rodenticide toxicosis in dogs and cats: a retrospective study.

Background: Ingestion of anticoagulant rodenticide is among the most common toxicoses seen in dogs and cats. Current treatment protocols in veterinary patients recommend the use of plasma-containing blood products to replenish clotting factors. Intravenous mixed-micelle phytomenadione (MMP) represents a safe and cost-effective alternative to traditional therapy.

Objective: Description of the use of MMP as a treatment for clinical anticoagulant rodenticide toxicosis, focusing on the incidence of adverse reactions and restoration of coagulation times. Duration of hospitalisation, cost of treatment and need for red blood cell-containing products were compared between two cohorts of patients receiving MMP and traditional therapy with blood products.

Methods: Retrospective search of electronic medical records from two Australian emergency and referral hospitals for patients treated for clinical anticoagulant rodenticide toxicosis between July 2021 and July 2024.

Results: 74 animals (71 dogs, 3 cats) were treated for anticoagulant rodenticide toxicosis within the study period. 44 dogs comprised the "control" group, and 27 dogs and 3 cats comprised the "MMP" group. One dog was excluded from each group. There was no difference in survival to discharge between groups (P = 0.28). No adverse reactions to MMP were recorded. Dogs within the "control" group were significantly more likely to receive fresh frozen plasma (FFP), there was no difference in requirement for red blood cell-containing products between groups (P = 1). Animals in the MMP group had significantly shorter hospitalisation time when compared with the control group (P = 0.01).

Conclusion: Based on red cell transfusion requirements and survival data in this case series, it can be suggested that MMP is a comparable and cost-effective treatment alternative for clinical anticoagulant rodenticide toxicosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Australian Veterinary Journal
Australian Veterinary Journal 农林科学-兽医学
CiteScore
2.40
自引率
0.00%
发文量
85
审稿时长
18-36 weeks
期刊介绍: Over the past 80 years, the Australian Veterinary Journal (AVJ) has been providing the veterinary profession with leading edge clinical and scientific research, case reports, reviews. news and timely coverage of industry issues. AJV is Australia''s premier veterinary science text and is distributed monthly to over 5,500 Australian Veterinary Association members and subscribers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信